Prognostic significance of co-expression of nm23 and p57 protein in hepatocellular carcinoma

Hepatology Research

Volumn 40, Issue 11, 2010, Pages 1107-1116

  Guo, Hui ^a   Nan, Kejun ^a   Hu, Tinghua ^a   Meng, Jie ^b   Hui, Wentao ^c   Zhang, Xiaozhan ^d   Qin, Haixia ^a   Sui, Chenguang ^a  

^a First Affiliated Hospital   (China)

^b The First people's Hospital of Yangzhou   (China)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^d Macao Special Administrative Region of the People's Republic of China   (Macao)

Author keywords

Hepatocellular carcinoma; Nm23; P57; Prognosis; Proliferation and apoptosis

Indexed keywords

CELL CYCLE PROTEIN; MOLECULAR MARKER; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PROTEIN P15; PROTEIN P57; PROTEIN P73; SURVIVIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; NICK END LABELING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 77958613883     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00721.x     Document Type: Article

References (39)

1. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008; 7: 237-57.
2. Teoh NC. Proliferative drive and liver carcinogenesis: too much of a good thing? J Gastroenterol Hepatol 2009; 24: 1817-25.
3. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15: 513-20.
4. Nishida N, Fukuda Y, Ishizaki K, Nakao K. Alteration of cell cycle-related genes in hepatocarcinogenesis. Histol Histopathol 1997; 12: 1019-25.
5. Song IH. Molecular targeting for treatment of advanced hepatocellular carcinoma. Korean J Hepatol 2009; 15: 299-308.
6. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004; 130: 497-513.
7. Besson A, Assoian RK, Roberts JM. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nat Rev Cancer 2004; 4: 948-55.
8. Yu HB, Han XB, Liang YQ, Liu JG, Wang H. [Expression of osteopontin and survivin in prostate cancer and the clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 1141-3.
9. Zhu H, Hu Y, Shuai CX, Shi ZZ, Zhang HX. [Expression of survivin, bcl-2 in cervical carcinoma and its association with HPV16/18 infection]. Zhonghua Yi Xue Za Zhi 2010; 90: 469-73. [In Chinese.
10. Kim HD, Youn B, Kim TS, Kim SH, Shin HS, Kim J. Regulators affecting the metastasis suppressor activity of Nm23-H1. Mol Cell Biochem 2009; 329: 167-73.
11. Choudhuri T, Murakami M, Kaul R et al. Nm23-H1 can induce cell cycle arrest and apoptosis in B cells. Cancer Biol Ther 2010; 9
12. Yamamoto K, Takenaka K, Kajiyama K et al. Cell proliferation and cell loss in nodule-in-nodule hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 813-9.
13. Kanthan R, Fried I, Rueckl T, Senger JL, Kanthan SC. Expression of cell cycle proteins in male breast carcinoma. World J Surg Oncol 2010; 8: 10.
14. Li B, Liu W, Wang L et al. CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma. Ann Surg Oncol 2010; 17: 1917-26.
15. Nozoe T, Honda M, Inutsuka S, Korenaga D. p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma. J Cancer Res Clin Oncol 2003; 129: 498-502.
16. Ubersax JA, Woodbury EL, Quang PN et al. Targets of the cyclin-dependent kinase Cdk1. Nature 2003; 425: 859-64.
17. Kabbarah O, Nogueira C, Feng B et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One 2010; 5
18. Fan GK, Xu F, Yang B, Fujieda S. p57(kip2) expression is related to carcinogenesis and tumor progression in laryngeal tissues. Acta Otolaryngol 2006; 126: 301-5.
19. Mann CD, Neal CP, Garcea G et al. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007; 43: 979-92.
20. Lombardi D. Commentary: nm23, a metastasis suppressor gene with a tumor suppressor gene aptitude? J Bioenerg Biomembr 2006; 38: 177-80.
21. Miyamoto M, Iwashita S, Yamaguchi S, Ono Y. Role of nm23 in the regulation of cell shape and migration via Rho family GTPase signals. Mol Cell Biochem 2009; 329: 175-9.
22. Murakami M, Meneses PI, Lan K, Robertson ES. The suppressor of metastasis Nm23-H1 interacts with the Cdc42 Rho family member and the pleckstrin homology domain of oncoprotein Dbl-1 to suppress cell migration. Cancer Biol Ther 2008; 7: 677-88.
23. Jin L, Liu G, Zhang CH et al. Nm23-H1 regulates the proliferation and differentiation of the human chronic myeloid leukemia K562 cell line: a functional proteomics study. Life Sci 2009; 84: 458-67.
24. Yang Y, Lu S, Li MF, Wang ZH. [Effects of tumor metastasis suppressor gene nm23-H1 on invasion and proliferation of cervical cancer cell lines]. Ai Zheng 2009; 28: 702-7.
25. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008; 14: 159-69.
26. Yokoo T, Toyoshima H, Miura M et al. p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus. J Biol Chem 2003; 278: 52919-23.
27. Vlachos P, Joseph B. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics. Oncogene 2009.
28. Hlupic L, Jakic-Razumovic J, Bozikov J et al. Prognostic value of different factors in breast carcinoma. Tumori 2004; 90: 112-9.
29. Kanat O, Adim S, Evrensel T et al. Prognostic value of nm23 in gastrointestinal stromal tumors. Med Oncol 2004; 21: 53-8.
30. Nakai S, Masaki T, Shiratori Y et al. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol 2002; 20: 769-75.
31. Yang X, Karuturi RK, Sun F et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 2009; 4: e5011.
32. Atasoy P, Yilmaz E, Bozdogan O, Ayva S, Batislam E. Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a). Int Urol Nephrol 2009; 41: 55-60.
33. Van Niekerk D, Guillaud M, Matisic J et al. p16 and MIB1 improve the sensitivity and specificity of the diagnosis of high grade squamous intraepithelial lesions: methodological issues in a report of 447 biopsies with consensus diagnosis and HPV HCII testing. Gynecol Oncol 2007; 107: S233-40.
34. Kallakury BV, Sheehan CE, Ambros RA et al. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 1997; 80: 753-63.
35. Chang HJ, Yoo BC, Kim SW et al. Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 2007; 13: 326-35.
36. Akaishi K, Nakayama J, Sakai K et al. Antigen p57/Kip2 as a potential negative regulator of human astrocytoma growth. J Clin Neurosci 2009; 16: 1615-8.
37. Puig P, Capodieci P, Drobnjak M et al. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res 2003; 9: 5642-51.
38. Fields AC, Cotsonis G, Sexton D et al. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 2004; 17: 1378-85.
39. Bal A, Joshi K, Logasundaram R et al. Expression of nm23 in the spectrum of pre-invasive, invasive and metastatic breast lesions. Diagn Pathol 2008; 3: 23.